Abstract
Small cell lung cancer (SCLC) displays high genomic instability. Therefore, targeting key proteins involved in maintaining genomic stability, such as ataxia telangiectasia and Rad3-related (ATR) protein kinase and topoisomerase I (TOP1), is a rational treatment strategy for SCLC. Berzosertib (M6620), an intravenous, highly potent and selective, first-in-class ATR inhibitor, is well tolerated and synergizes with topotecan (TOP1 inhibitor) in patients with advanced solid tumors, particularly those with platinum (plt)-resistant SCLC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
